Literature DB >> 2318227

Hypertrophic cardiomyopathy: is a left ventricular outflow tract gradient a major prognostic determinant?

F Romeo1, F Pelliccia, R Cristofani, E Martuscelli, A Reale.   

Abstract

The relationship of left ventricular outflow tract gradient as well as of clinical, ECG and haemodynamic data to presenting features and prognosis was evaluated in 125 consecutive patients with hypertropic cardiomyopathy, 79 men and 46 women (mean age: 34 +/- 7 years) studied between January 1970 and December 1985. Most clinical, ECG and haemodynamic findings were similar in the 44 patients (35%) with a pressure gradient (greater than or equal to 30 mmHg) and in the 81 patients (65%) without. Those with obstruction had greater ECG voltage SV1 and RV5; however, higher grade ventricular arrhythmias were more common in patients without obstruction. During a mean follow-up period of 7.6 +/- 4.5 years (range 2-18 years), death from a cardiac cause occurred in 28 patients (21 died suddenly) and was significantly less common in patients with a pressure gradient than in those without (11% vs 28%, P = 0.039). Univariate analysis of survival curves showed that the most powerful predictors of a poor prognosis were ejection fraction P = 0.0001), mean pulmonary artery pressure (P = 0.0001), dyspnoea (P = 0.001), left ventricular end-diastolic pressure (P = 0.002), complex ventricular arrhythmias (P = 0.029) and severe mitral regurgitation (P = 0.037). Using multivariate analysis, a decreased ejection fraction (P = 0.006) and a raised mean pulmonary artery pressure (P = 0.022) were the only independent prognostic determinants. Thus, the presence of a left ventricular outflow tract gradient does not seem of adverse prognostic significance. Risk factor characterization in patients with hypertrophic cardiomyopathy may be improved by assessment of ventricular arrhythmias in the context of left ventricular function.

Entities:  

Mesh:

Year:  1990        PMID: 2318227     DOI: 10.1093/oxfordjournals.eurheartj.a059689

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  10 in total

1.  Alcohol catheter ablation of atrioventricular conduction.

Authors:  A D Cunningham; E Rowland
Journal:  Br Heart J       Date:  1991-03

Review 2.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 3.  Cardiopulmonary exercise testing in the assessment of pulmonary hypertension.

Authors:  Ross Arena; Marco Guazzi; Jonathan Myers; Daniel Grinnen; Daniel E Forman; Carl J Lavie
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

4.  Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy.

Authors:  P M Elliott; J R Gimeno; R Thaman; J Shah; D Ward; S Dickie; M T Tome Esteban; W J McKenna
Journal:  Heart       Date:  2005-10-10       Impact factor: 5.994

5.  Screening for hypertrophic cardiomyopathy.

Authors:  A L Clark; A J Coats
Journal:  BMJ       Date:  1993-02-13

6.  Non-surgical ablation of the ventricular septum for the treatment of hypertrophic cardiomyopathy.

Authors:  C M Oakley
Journal:  Br Heart J       Date:  1995-11

7.  Natural history of hypertrophic cardiomyopathy.

Authors:  P M Elliott
Journal:  Curr Cardiol Rep       Date:  2000-03       Impact factor: 2.931

Review 8.  The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era.

Authors:  P M Elliott
Journal:  Curr Cardiol Rep       Date:  2001-03       Impact factor: 2.931

Review 9.  [Clinical picture and therapy of hypertrophic cardiomyopathy].

Authors:  U Gleichmann; H Seggewiss
Journal:  Med Klin (Munich)       Date:  1998-04-15

10.  Modes of death and clinical outcomes in adult patients with hypertrophic cardiomyopathy in Thailand.

Authors:  Nattakorn Songsirisuk; Veraprapas Kittipibul; Nilubon Methachittiphan; Vorawan Charoenattasil; Nath Zungsontiporn; Ittikorn Spanuchart; Saranya Buppajarntham; Charoen Mankongpaisarnrung; Sudarat Satitthummanid; Suphot Srimahachota; Pairoj Chattranukulchai; Smonporn Boonyaratavej Songmuang; Sarinya Puwanant
Journal:  BMC Cardiovasc Disord       Date:  2019-01-03       Impact factor: 2.298

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.